Ferguson Wellman Capital Management Inc. Sells 232 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Ferguson Wellman Capital Management Inc. reduced its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 4.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,141 shares of the company’s stock after selling 232 shares during the period. Ferguson Wellman Capital Management Inc.’s holdings in GE HealthCare Technologies were worth $482,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in GEHC. Vanguard Group Inc. boosted its holdings in GE HealthCare Technologies by 9.2% in the first quarter. Vanguard Group Inc. now owns 48,519,340 shares of the company’s stock valued at $4,410,893,000 after acquiring an additional 4,107,746 shares during the last quarter. Capital Research Global Investors boosted its holdings in shares of GE HealthCare Technologies by 5.2% during the 1st quarter. Capital Research Global Investors now owns 53,991,923 shares of the company’s stock worth $4,908,406,000 after buying an additional 2,647,204 shares in the last quarter. Van ECK Associates Corp bought a new position in shares of GE HealthCare Technologies during the 3rd quarter worth approximately $208,513,000. Marshall Wace LLP bought a new position in shares of GE HealthCare Technologies during the 2nd quarter worth approximately $63,639,000. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in shares of GE HealthCare Technologies by 4,959.8% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 758,514 shares of the company’s stock worth $68,957,000 after buying an additional 743,523 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.

GE HealthCare Technologies Trading Down 1.5 %

Shares of GE HealthCare Technologies stock opened at $82.92 on Friday. GE HealthCare Technologies Inc. has a 1 year low of $66.39 and a 1 year high of $94.55. The firm has a market cap of $37.88 billion, a PE ratio of 22.78, a P/E/G ratio of 3.02 and a beta of 1.24. The stock has a fifty day moving average price of $88.76 and a 200-day moving average price of $83.48. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.98.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.08. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. The firm had revenue of $4.86 billion during the quarter, compared to analyst estimates of $4.87 billion. During the same period last year, the firm posted $0.99 EPS. The business’s revenue was up .9% compared to the same quarter last year. Equities research analysts anticipate that GE HealthCare Technologies Inc. will post 4.29 EPS for the current year.

GE HealthCare Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Friday, October 18th will be given a dividend of $0.03 per share. This represents a $0.12 annualized dividend and a dividend yield of 0.14%. The ex-dividend date of this dividend is Friday, October 18th. GE HealthCare Technologies’s dividend payout ratio is presently 3.30%.

Wall Street Analyst Weigh In

GEHC has been the topic of a number of research analyst reports. Wells Fargo & Company increased their price target on GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. UBS Group cut GE HealthCare Technologies from a “neutral” rating to a “sell” rating and cut their price target for the stock from $84.00 to $74.00 in a report on Thursday, September 26th. BTIG Research upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Wednesday, September 18th. Stifel Nicolaus upped their target price on GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. Finally, Redburn Atlantic raised GE HealthCare Technologies to a “strong-buy” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $94.36.

Insider Transactions at GE HealthCare Technologies

In other news, CEO Roland Rott sold 3,577 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the transaction, the chief executive officer now owns 24,298 shares in the company, valued at approximately $2,101,291.04. This represents a 12.83 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.27% of the stock is owned by corporate insiders.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.